Jaeb Center for Health Research

A recent review published in JAMA authored by GCDTR’s @JacobsenLM and Desmond A. Schatz highlights key advances in understanding autoimmune mechanisms, early detection, and evolving treatment strategies. pubmed.ncbi.nlm.nih.gov/41697686/

Primary results from the CALEC study were published in March of last year and still generating plenty of interest, check out this write up in Nat Geo! nationalgeographic.com/health/article…

JAEB was well represented at ATTD last week check out the highlights!

Interesting debate at #ATTD2026 : Is it time for continuous glucose monitoring metrics to replace hemoglobin A1c in #diabetes management? medscape.com/viewarticle/a1…

Results from the INHALE-1 study focusing on treatment of post-meal hyperglycemia came out last week in Diabetes Technology & Therapeutics! journals.sagepub.com/doi/10.1177/15…

Our founder and senior medical director Dr. Roy Beck sat down with Endocrine Today to discuss the implications of the T2IQP study! healio.com/news/endocrino…

Results from the 52-week extension to the INHALE-1 study were published in Diabetes Technology & Therapeutics last month! journals.sagepub.com/doi/10.1177/15…

Diabetes is the nation's most expensive chronic disease, costing our economy nearly $413 billion annually. At Call to Congress and every day, we call for robust federal resources for prevention, treatment, and research to end the diabetes epidemic. #ADACall2Congress

🚀Hello from #ATTD2026! Four days of innovation in diabetes tech and care begin today. Sessions start at 09:00, including ATTD Ignite. Join us tonight for the Opening Session & Welcome Reception. 🔗attd.kenes.com/scientific-pro… #DiabetesTech #DiabetesInnovation

💡 Dr. Roy Beck of @JaebCenter shares why children with #diabetes using technosphere #insulin had an increase in HbA1c over 1 year. Read our full coverage of the INHALE-1 extension study ⬇️ @MannKindCorp @IDinChildren vist.ly/4u6ix

Attending ATTD in Barcelona this week? Be sure to check out the latest presentations from JCHR. Our teams are sharing impactful work focused on advancing innovation, improving outcomes, and shaping the future of diabetes care.

“A1C can lie. Time in range does not.” — Sugar Queens’ @JenniferGoldman explains why CGM is standard of care in T1D, and why evidence-based pregnancy care increasingly depends on it for insulin use in T2D. WATCH HERE: mdsc.pe/4uc9ZEU

Attending ATTD in Barcelona next week? Don’t miss the Leona M. and Harry B. Helmsley Charitable Trust Symposium focused on exercise and type 1 diabetes. If exercise and T1D are part of your work, or your passion, this is one you’ll want on your schedule. We hope to see you there!

Attending ATTD in Barcelona next week? Be sure to check out the latest presentations from JCHR! Our teams are sharing impactful work focused on advancing innovation, improving outcomes, and shaping the future of diabetes care.

Protocol Chair Dr. Alberto Pugliese stopped by the Clinical Trial Th1nk Tank podcast to discuss the WAVE T1D study! youtube.com/watch?v=iUE1Lq…

🗣️ Hear more from Dr. Roy Beck of @JaebCenter as he discusses his recently published study analyzing HbA1c change around subgroups of adults with type 2 #diabetes in the 2IQP trial. Read the full story 👇 @GoHealio vist.ly/4rg3w

Our Diabetes Publications 2025 Year in Review is out now!

@grekbote @DiabetesCareADA @AmDiabetesAssn @ADA_DiabetesPro @ADA_Pubs The adults study results came out at the end of 2024; pmc.ncbi.nlm.nih.gov/articles/PMC11…

@DiabetesCareADA @AmDiabetesAssn @ADA_DiabetesPro @ADA_Pubs What about adults?

Inhaled technosphere insulin can be safely used in children with diabetes and is associated with greater treatment satisfaction and less weight gain than conventional injectable insulin. Read here ➡️ doi.org/10.2337/dc25-1… @AmDiabetesAssn @ADA_DiabetesPro @ADA_Pubs

· If you have been living with type 1 diabetes for at least 1 year and are 18 or older, we want to hear from you! Learn more about our online educational study on exercise today!